UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
December 1, 2003
Date of report (Date of earliest event reported)
ENCORE MEDICAL CORPORATION
(Exact name of Registrant as Specified in Charter)
| Delaware | | 000-26538 | | 65-0572565 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| 9800 Metric Blvd., Austin, Texas | | 78758 |
| (Address of Principal Executive Offices) | | (Zip Code) |
(512) 832-9500
(Registrant’s telephone
number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
| Item 5. | | Other Events and Regulation FD Disclosure |
On December 1, 2003, Encore Medical Corporation (the “Company”) issued a press release to announce that the Company received pre-market approval from the U.S. Food and Drug Administration for its Keramos™ ceramic-on-ceramic acetabular hip replacement.
A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and is hereby incorporated by reference herein.
| Item 7. | | Financial Statements and Exhibits |
(c) Exhibits.
99.1 | | Press Release dated December 1, 2003. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | ENCORE MEDICAL CORPORATION |
| | | |
| Date: December 1, 2003 | | | | By: | | /s/ Harry L. Zimmerman |
| | | | | |
|
| | | | | | | | | Harry L. Zimmerman Executive Vice President – General Counsel |
2
EXHIBIT INDEX
Exhibit Number
| | Description
|
99.1 | | Encore Medical Corporation Press Release dated December 1, 2003 |
3
